VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
Kv1.3
October 18, 2024
By VRG Therapeutics
Press release
AI
Team
July 29, 2024
By VRG Therapeutics
VRG Therapeutics has been selected among the "Early Stage Startups to Watch" in the drug discovery space by Sifted!
Kv1.3
July 11, 2024
By VRG Therapeutics
New VRG Tx patent application filed!
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.